The current treatment of breast cancer, the most frequent malignancy found in females, requires the study of biomarkers. The standard set of these includes at least an estrogen receptor, a progesterone receptor and a HER2 receptor, although many other factors have been shown to contribute to the prognosis. Tissue microarrays have been introduced to decrease costs and workload of immunohistochemistry applied to large collections of samples. The aim of the study was to test the performance of this technology on three basic biomarkers of breast carcinoma in 106 cases of invasive breast carcinoma. Tissue microarrays composed of 3 cores sized 0.6 mm per case were constructed and stained by standard immunohistochemistry. The results were assessed on virtual slides created with an Aperio scanner. A sensitivity and specificity of 0.83 and 0.88 was obtained for the estrogen receptor, 0.76 and 0.88 for the progesterone receptor, 0.69 and 0.96 for HER2. In conclusion, TMA technology may give results comparable to the diagnosis based on whole sections, and the clinicopathologic correlations for the immunohistochemistry performed by both methods are fairy similar.
Introduction
As the most frequent cancer occurring in females, breast carcinoma (BC) is a disease of an outstanding importance both for clinician and pathologist. Although the primary classification is done by standard histopathology, immunohistochemistry is increasingly used both for classification and prognosis. The routinely used immunohistochemical (IHC) methods include determination of receptor status, namely estrogen receptor (ER), progesterone receptor (PR) and HER2. These define three main classes of BC: steroid receptor dependent (ER+, PR+, HER2-), HER2 dependent (ER-, PR-, HER2+) and triple negative (ER-, PR-, HER2-). These categories differ in their aggressiveness as well as treatment. Many other biomarkers were also shown to contribute to the prognosis, and some are on the way to become diagnostic standards [1] [2] [3] . Currently, immunohistochemistry for ER, PR and HER2 should be performed in every case of BC; the side effects in the diagnostic therapeutic improvement are the increased costs of histological examination.
Tissue microarrays (TMA) are commonly used to reduce costs and efficacy of biomarker assessment. This method combines material from several tissue blocks into a single recipient block, reducing the costs and labor considerably, however, at the expense of lower representativeness. Some authors proposed the use of TMAs for routine IHC classification of BC while others advocated more caution in this regard [4] [5] [6] [7] . Since our lab has specific experience in using the TMA method both for immunohistochemistry and in situ hybridization, we decided to test the feasibility of TMA assessment of receptor status in BC and compare them with the results obtained by routine immunohistochemistry. We wanted also to see how many cases would be lost from the TMA assay, and how this loss would influence overall results of the receptor assays.
Material and methods
The material consisted of 106 unselected archival cases of invasive ductal breast carcinoma. The clinicopathologic www.fhc.viamedica.pl data is shown in Table 1 . The hematoxylin and eosin stained slides were evaluated microscopically and the ones containing areas of best-preserved cancer tissue were chosen for TMA construction. The source area was marked on the slide, copied onto paraffin block and tissue cores were transferred into recipient block. The TMAs were constructed using MTA1 device (Beecher Instruments, Sun Prairie, WI, USA) ( Figure 1) . From each case, 3 cores sized 0.6 mm were extracted. From the blocks, 2µm sections were prepared and used for immunohistochemistry. The immunohistochemistry for ER and PR was done by routine manual method. Briefly, the slides were de-waxed, rehydrated and incubated in 3% peroxide solution for 10 minutes to block the endogenous peroxidase activity. Antigen retrieval was carried out by heating in citrate buffer for 30 minutes. The Lab-Vision detection system was used. The slides were scanned with Aperio CS device (Aperio Inc., Vista, CA, USA) and virtual slides visually reviewed and scored. For the evaluation of estrogen and progesterone receptors, the percentage of strongly positively stained nuclei was assessed. For HER2 assessment, the cores were classified into the standard categories according to ASCO/CAP guidelines [8] . Cases 0 and 1+ on HER2 are refferend to as 'negative', cases 2+ as 'ambigous', and 3+ as 'positive'. This is in concordance with the clinical meaning of the HER2 assay: in 3+ cases anti-HER2 antibodies are used for treatment, 2+ cases require in situ hybridisation before therapy choice, while 0 and 1+ cases are treated by other methods. The results of standard (whole sections) immunohistochemistry performed manually were obtained from the department's files.
Statistical analysis. The statistical analysis was done using Excel 2010 (Microsoft, Redmond, WA, USA), Statistica 10 (StatSoft, Tulsa, OK, USA) and QuickCalcs (GraphPad Software Inc., La Jolla, CA, USA http://graphpad.com/quickcalcs/) programs. Pearson's c 2 , Mann-Whithey U test, kappa statistics were used, as deemed appropriate. Bland-Altman analysis was performed with Statistica software with a macro written by Matt Coates, available from http://sdn.statsoft. com/STATISTICAVisualBasicExamples/BlandAltmanPlot. aspx. The correlation between variables was assessed by Spearman's correlation coefficient. The significance level was set to P < 0.05. Figure 1 . One of the routine tissue microarray slides used in the study. Notice the asymmetric arrangement of individual cores, necessary for proper orientation. Also, the loss of some cores may be appreciated www.fhc.viamedica.pl
Results
On whole-slide immunohistochemistry which had been performed manually, the average percentage of ER positive cells was 68.61% (range 0 to 100, SD 36.65).
The average percentage of PR positive cells was 60.45% (0 to 100, 39.98: range and SD, respectively). HER2 The results of whole-slide and TMA assessment strongly correlated (for ER r = 0.66 P < 0.001; for PR r = 0.73 P < 0.001; for HER2 r = 0.62 P < 0.001). However, the results obtained by both methods were not identical. The mean difference for ER was 12.91% (range -68 to 100, SD 32.89), for PR 11.53% (range -99 to 90 SD 33.71), and for HER2 0.59% (range -1 to 3, SD 0.8). Tables 1 to 3 and Figure 5 show the relationships between clinically relevant receptor immunoreactivities assessed in standard, manually stained histologic slides and TMAs. It is evident that use of TMA has high positive predictive value specificity yet lower negative predictive value and sensitivity. There was no difference in number of available cores between concordant and discordant cases.
The ER, PR and HER2 status did not show significant differences between pT stages, both in case of whole-slide and TMA immunohistochemistry (data not shown). As might have been expected, there was a statistically significant relationship between the grade of the tumor and receptor status: higher grade cancers tended to be ER and PR negative and HER2 positive more often than the lower grade. These relationships were similar for both whole-slide and TMA immunohistochemistry ( Figure 6 ).
Discussion
The study of biomarkers considerably increases the effectiveness of cancer prognosis and treatment. Often the multivariate analysis of biomarkers and morphologic features offers quite good discrimination between groups; however, in the routine diagnostic workup, the principal limit is the increased cost and workload. The tissue microarray technology, introduced in the `90s, permitted the analysis of several cases within a single tissue block [9, 10] . The advantage of this approach is a dramatic reduction in expenses and laboratory workload. In fact, a single TMA may contain as many as hundreds of samples. This may result in a significant reduction of overall costs, especially if many markers are studied within a single experiment. IHC analysis of datasets containing thousands of cases is otherwise impossible or, at best, extremely difficult. Utilizing this method Tamini et al. [11] performed TMA analysis of a large cohort of over 3000 BC cases with sections stained for ER, PR, HER2, CK5/6 and EGFR. These authors used 3 0.6 mm cores for each case and reported to have used 23 TMA blocks. This results in a total of only 115 slides stained (23 × 5 = 115), while with standard technology, 15465 slides (3093 × 5 = = 15465) would be stained, a workload that would be prohibitive. As the result, the authors were able to reproduce molecular classification of the BC cases. Similarly, Callagy et al. [12] successfully used TMA immunohistochemistry for emulating molecular classification of breast cancer. TMAs may also be used for in situ hybridization studies [13] . Several choices have to be made before starting a TMA experiment. A principal one is the size of the array itself and the diameter of individual cores. The core size may range from 0.5 to 3 mm and 0.6 mm was applied in our study; while the arrays with smallest cores contain hundreds of cases, the ones with largest cores will consist of a few dozen samples only.
Despite its obvious advantages TMA technology suffers from some drawbacks. The principal one is the limited size of the core examined. A single core contains only a small fraction of the entire section which, by itself, represents only a small fraction of an www.fhc.viamedica.pl entire lesion. Thus, TMAs are most useful for detecting markers with a diffuse and uniform expression within a lesion. Although this technique may be less adequate for analyzing parameters which, by their nature, vary between various tumor tissue regions differing in microvessel density or tumor-related inflammatory infiltrate, we used it successfully for microvessel analysis [14] . Early and in situ lesions may be particularly difficult to be properly included in the TMAs [15] . Further progress may be obtained with TMA technology via integration with imaging systems, allowing computer-aided array design and scoring based on image-analysis. With this methodology, the possibility arises to choose cores from specific compartments, e.g. inside of the lesion, infiltration front, perilesional inflammatory infiltrate, etc. [16] . However, by using such approach, non-trivial problems will be encountered like separation of neoplastic from non-neoplastic cells, exclusion of poorly preserved tissue, and overlapping nuclei. Some of these problems may be solved using semiautomatic, human-manned systems. Unfortunately, this will limit the profits of automated analysis. Faratian et al. [17] have validated the uses of image analysis system for the evaluation of steroid receptors in breast cancer; they found that a sufficient accuracy may be obtained with just two cores and an excellent accuracy with six cores. Additionally, the use of virtual slides technology, like in the present study, may help the manual assessment. Another drawback of the TMA technique is the tissue core loss. Inevitably, even in experienced hands, some tissue cores may contain no tumor and others may be positioned outside the plane of section. Furthermore, during the staining procedure, especially during antigen retrieval, some of the cores are lost. To limit the influence of tissue loss the usual procedure is to include several cores from a single case which limits the advantages of the technology. On the other hand, [19] analyzed the results of TMA assessment of HER2 in breast cancer; they used only one 0.6 core per case and reported high accuracy of the method. Highest discordance rates were seen for 2+ staining cases. According to these authors 2+ cases should be reevaluated using immunohistochemistry and FISH on whole slides [19] . Graham et al. [20] also advocated for the practical application of TMA for HER2 evaluation in BC, yet reported that 5 cores were needed for proper assessment of the marker and obtained extremely good (> 95%) agreement between whole slides and TMAs. Kyndi et al. [21] analyzed the problem of staining heterogeneity encountered by including TMA cores from different paraffin blocks and different parts of the block. They reported very significant concordance of the results for a single breast tumor and concluded that a single core was sufficient for consistent evaluation. Conversely, Lin et al. [7] concluded that TMA concordance with standard immunohistochemistry strongly depended on the number of cores studied. The ranges of specificity and sensitivity seen by Lin et al. were similar to those found in our study. Lin et al. concluded that TMA should be used for biomarker research, however caution is advised when applying this technology for the purposes of diagnostic pathology. On a small series of cases, Awadelkarim et al. [5] by comparing TMAs with classical IHC evaluation reported for TMAs sensitivities of 77.8%, 82.8%, 83.3%, and negative predictive values of 64.7%, 72.2%, 96.4% for ER, PR and HER2, respectively. Their results were thus similar to ours but no relationship was found between the tumor size and TMA accuracy in our material.
TMAs were also extensively used for quality assurance and control, facilitating the process of the same staining on several tissues, allowing for the identification of discrepancies. Thus, in Wasielewski et al. study [22] tumors with more ambiguous staining results tended to show higher inter-observer and inter-laboratory variability. Diaz et al. [23] specifically tested the feasibility of TMAs for validation of HER2 FISH test. In this setting, the tissue microarrays were stained in different laboratories and the results were compared. These authors reported a perfect concordance in all the informative cases. Programs of quality control on TMAs have been also introduced in Poland for the validation of HER2 FISH test (External Quality Assessment Scheme, run by Abbott Molecular).
In conclusion, we showed that tissue microarray technology may provide results comparable to whole sections in assessing receptor immunohistochemistry of breast carcinoma. The positive results were highly consistent, yet negative predictive value was not entirely satisfactory. Nevertheless, the relationship between clinicopathologic data and immunohistochemistry performed on whole slides and TMAs were found to be fairy similar.
